Journal rankings · indicator year 2024
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Field ranking · 2024
Pharmacology, Toxicology and Pharmaceutics journal rankings 2024
72 ranked journals · Field in Life Sciences
Pharmacology, Toxicology and Pharmaceutics has 72 ranked journals in 2024. The median journal has an OJR of 0.63, below the world average of 1.00, unchanged on 2023; Q1 starts at OJR 1.13. The top three are Drug Delivery, Drug Delivery and Translational Research, and International Journal of Pharmaceutics X.
Ranks and citation indicators: 2024. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2021–2023, the window the 2024 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields in Pharmacology, Toxicology and Pharmaceutics (4)
Up to Life Sciences72 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2023. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2021–2023, the window the 2024 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2021–2023 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2015 to 2024. | Compare |
|---|---|---|---|---|---|---|---|
1Drug DeliveryOATaylor & Francis · United Kingdom | 2.19Q1 | 9.14 1.98 up from 2023 | 600 | 100% | $2,864 | ||
2Drug Delivery and Translational ResearchSpringer Science+Business Media · United States | 1.73Q1 | 6.08 0.43 down from 2023 | 597 | 51% | $4,690 | ||
3International Journal of Pharmaceutics XOAElsevier BV · Netherlands | 1.67Q1 | 6.87 1.01 up from 2023 | 143 | 100% | $2,590 | ||
4Expert Opinion on Drug DeliveryTaylor & Francis · United Kingdom | 1.60Q1 | 6.13 0.64 up from 2023 | 287 | 32% | — | ||
5International Journal of PharmaceuticsElsevier BV · Netherlands | 1.50Q1 | 5.77 0.18 down from 2023 | 3,043 | 40% | $4,650 | ||
6Drug SafetyAdis, Springer Healthcare · New Zealand | 1.47Q1 | 4.19 0.23 down from 2023 | 324 | 74% | $4,990 | ||
7Journal of Pharmaceutical InvestigationSpringer Science+Business Media · South Korea | 1.46Q1 | 5.97 0.05 down from 2023 | 149 | 18% | $3,890 | ||
8Future Journal of Pharmaceutical SciencesOASpringer Science+Business Media · Egypt | 1.43Q1 | 4.06 0.92 down from 2023 | 421 | 100% | $0 listed | ||
9Expert Opinion on Drug Metabolism & ToxicologyTaylor & Francis · United Kingdom | 1.43Q1 | 3.43 0.79 down from 2023 | 220 | 25% | — | ||
10European Journal of Pharmaceutical SciencesOAElsevier BV · Netherlands | 1.41Q1 | 4.90 0.05 down from 2023 | 806 | 100% | $3,070 | ||
11European Journal of Pharmaceutics and BiopharmaceuticsElsevier BV · Netherlands | 1.33Q1 | 4.67 0.27 down from 2023 | 677 | 50% | $4,210 | ||
12Journal of Drug Delivery Science and TechnologyElsevier BV · France | 1.28Q1 | 5.49 0.60 up from 2023 | 2,663 | 22% | $3,810 | ||
13Clinical and Translational ScienceOAWiley · United Kingdom | 1.25Q1 | 3.43 0.03 down from 2023 | 684 | 100% | $3,630 | ||
14Drug Metabolism and DispositionAmerican Society for Pharmacology and Experimental Therapeutics · United States | 1.23Q1 | 3.68 0.33 down from 2023 | 429 | 66% | $3,500 | ||
15ADMET & DMPKOAInternational Association of Physical Chemists (IAPC) · Croatia | 1.16Q1 | 4.44 0.63 up from 2023 | 81 | 100% | — | ||
16AAPS PharmSciTechSpringer Science+Business Media · United States | 1.15Q1 | 4.61 0.55 up from 2023 | 790 | 25% | $4,190 | ||
17Pharmaceutical ResearchSpringer Science+Business Media · United States | 1.14Q1 | 4.63 0.62 up from 2023 | 633 | 39% | $4,690 | ||
18Forensic ToxicologySpringer Science+Business Media · Japan | 1.13Q1 | 2.94 0.02 up from 2023 | 109 | 45% | $2,990 | ||
19Expert Opinion on Drug SafetyTaylor & Francis · United Kingdom | 1.03Q2 | 3.44 0.03 down from 2023 | 430 | 15% | — | ||
20The Pharmacogenomics JournalSpringer Nature · United Kingdom | 1.02Q2 | 3.59 0.08 up from 2023 | 111 | 46% | $4,890 | ||
21AAPS OpenOASpringer Nature · Germany | 0.97Q2 | 3.45 0.67 up from 2023 | 50 | 100% | $2,090 | ||
22Journal of Analytical ToxicologyOxford University Press · United Kingdom | 0.97Q2 | 3.01 0.43 up from 2023 | 307 | 55% | $4,823 | ||
23Journal of MicroencapsulationTaylor & Francis · United Kingdom | 0.95Q2 | 3.38 0.08 down from 2023 | 128 | 6% | — | ||
24European Journal of Drug Metabolism and PharmacokineticsAdis, Springer Healthcare · France | 0.95Q2 | 2.54 0.45 up from 2023 | 200 | 32% | $2,690 | ||
25Drug Metabolism and PharmacokineticsElsevier BV · Japan | 0.88Q2 | 2.04 0.88 down from 2023 | 143 | 16% | $3,580 | ||
26Scientia PharmaceuticaOAÖsterreichische Apotheker-Verlagsgesellschaft m. b. H. · Switzerland | 0.86Q2 | 2.87 0.07 down from 2023 | 177 | 100% | $1,207 | ||
27Frontiers in Drug Safety and RegulationOAFrontiers Media · Switzerland | 0.82Q2 | 2.26 0.12 up from 2023 | 44 | 100% | $2,353 | ||
28Drug Testing and AnalysisWiley · United States | 0.77Q2 | 2.77 0.05 down from 2023 | 544 | 63% | $4,440 | ||
29Drug Development and Industrial PharmacyTaylor & Francis · United States | 0.77Q2 | 2.69 0.06 up from 2023 | 310 | 7% | — | ||
30Forensic ChemistryElsevier BV · Netherlands | 0.74Q2 | 2.49 0.40 down from 2023 | 218 | 49% | $4,530 | ||
31Pharmaceutical Development and TechnologyTaylor & Francis · United States | 0.72Q2 | 2.64 0.05 down from 2023 | 262 | 15% | — | ||
32Critical Reviews in Therapeutic Drug Carrier SystemsBegell House · United States | 0.70Q2 | 2.86 0.09 down from 2023 | 58 | 6% | — | ||
33PharmacogenomicsFuture Medicine · United Kingdom | 0.69Q2 | 1.93 0.01 up from 2023 | 273 | 78% | — | ||
34Current Drug DeliveryBentham Science Publishers · Netherlands | 0.69Q2 | 3.15 0.76 up from 2023 | 391 | 10% | — | ||
35Biopharmaceutics & Drug DispositionWiley · United Kingdom | 0.66Q2 | 2.32 0.61 up from 2023 | 94 | 63% | $3,800 | ||
36Pharmacogenetics and GenomicsLippincott Williams & Wilkins · United Kingdom | 0.63Q2 | 1.63 0.47 down from 2023 | 92 | 30% | — | ||
37Turkish Journal of Pharmaceutical SciencesOAGalenos Yayinevi · Türkiye | 0.62Q3 | 1.29 0.52 down from 2023 | 244 | 100% | — | ||
38Journal of Pharmaceutical InnovationSpringer Science+Business Media · United Kingdom | 0.61Q3 | 2.08 0.15 down from 2023 | 268 | 18% | $3,990 | ||
39Current Drug MetabolismBentham Science Publishers · Netherlands | 0.58Q3 | 1.84 0.11 down from 2023 | 264 | 15% | — | ||
40Journal of Pharmaceutical Health Care and SciencesOABioMed Central · United Kingdom | 0.57Q3 | 1.34 0.15 down from 2023 | 135 | 100% | $2,490 | ||
41RPS Pharmacy and Pharmacology ReportsOxford University Press | 0.57Q3 | 1.71 0.29 down from 2023 | 48 | 96% | $2,852 | ||
42Drug Metabolism and Bioanalysis LettersBentham Science Publishers | 0.55Q3 | 1.53 0.43 up from 2023 | 37 | 0% | — | ||
43Therapeutic DeliveryFuture Science Ltd · United Kingdom | 0.53Q3 | 1.91 0.07 down from 2023 | 162 | 80% | — | ||
44Assay and Drug Development TechnologiesMary Ann Liebert, Inc. · United States | 0.48Q3 | 2.15 0.37 up from 2023 | 109 | 15% | — | ||
45Pharmaceutical NanotechnologyBentham Science Publishers · Netherlands | 0.48Q3 | 2.05 0.05 up from 2023 | 140 | 3% | — | ||
46Pharmacology & PharmacyOAScientific Research Publishing · United States | 0.48Q3 | 1.64 0.61 up from 2023 | 99 | 100% | — | ||
47Recent Patents on NanotechnologyBentham Science Publishers · Netherlands | 0.46Q3 | 1.77 0.30 down from 2023 | 136 | 0% | — | ||
48Recent Advances in Drug Delivery and FormulationNetherlands | 0.43Q3 | 1.47 0.03 up from 2023 | 68 | 3% | — | ||
49Journal of Fluorine ChemistryElsevier BV · Netherlands | 0.40Q3 | 1.76 0.22 up from 2023 | 337 | 37% | $3,660 | ||
50Brazilian Journal of Pharmaceutical SciencesOAUniversity of São Paulo · Brazil | 0.40Q3 | 1.21 0.35 up from 2023 | 620 | 100% | — |
Subfields of Pharmacology, Toxicology and Pharmaceutics, compared.
Journals
Citations made in 2024. Corpus-wide, 87.1% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
16 additional Pharmacology, Toxicology and Pharmaceutics journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2021–2023, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2024. Publication window: 2021–2023. How these summaries are calculated
- Ranked journals
- 72
- Window papers (baseline)
- 56,944 +4.9% from indicator year 2021
- Median OJR
- 0.625 +0.7% from indicator year 2021
- Rising journals (2025)
- 4Comparison-group list (4)
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2021–2023 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 23 | 27 | 30 | 32 | 32 | 34 | 37 | 38 | 40 | 43 | 44 | 49 | 54 | 61 | 69 | 71 | 74 | 71 | 73 | 75 | 70 | 72 | 75 | 73 | 72 | 68 | |
| Window papers (baseline) | 20,428 | 21,714 | 23,158 | 25,397 | 26,889 | 29,157 | 31,606 | 34,777 | 38,146 | 41,640 | 45,814 | 49,553 | 53,613 | 56,245 | 59,173 | 59,681 | 59,061 | 56,321 | 53,536 | 51,719 | 51,606 | 54,267 | 56,608 | 57,539 | 56,944 | 58,541 | |
| Median OJR | 0.620 | 0.717 | 0.722 | 0.88 | 0.86 | 0.83 | 0.91 | 1.11 | 0.9471 | 0.97 | 0.949 | 1.03 | 0.9469 | 0.80 | 0.70 | 0.720 | 0.61 | 0.7184 | 0.74 | 0.628 | 0.77 | 0.621 | 0.67 | 0.630 | 0.625 | 0.7176 |
| Measure | Category statistic | Eligible population |
|---|---|---|
| Journal self-citation share | Median: 2.7% | 62 journals |
| Retracted papers per 1,000 | Pooled rate: 1.221 per 1,000 | 51 journals |
| Output growth | Median: -1.6% | 60 journals |
| Open access share | Median: 44.5% | 68 journals |
| Listed APC (USD) | Median including $0 listed prices: $3,605 | 32 ranked journals with a known listed price, including $0 listed prices |
| International collaboration share | Median: 22.2% | 67 journals |
| Review share | Median: 0.4% | 68 journals |
| Articles-only OJR | Median: 0.74 | 68 journals |
| Uncited share | Median: 25.2% | 68 journals |
| Citation concentration | Median: 43.7% | 68 journals |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.